Therapies are needed to limit progression of fatty liver diseases in patients with human immunodeficiency virus (HIV) infection. We analyzed data from a prospective study of the effects of rosuvastatin (a statin) on hepatic steatosis in HIV-positive adults.
W ith the development of potent antiretroviral therapy (ART) and the ensuing longer life expectancies for individuals with human immunodeficiency virus (HIV) infection, 1 other causes of morbidity and mortality are becoming increasingly recognized in this group. Liver disease has emerged as one of the leading causes of death among HIV-infected patients. 2 Much of the current challenge in liver disease in HIV is related to nonalcoholic fatty liver disease (NAFLD), and effective therapies aimed at limiting the progression of hepatic steatosis in this population are needed urgently. In the general population, NAFLD often is associated with obesity, insulin resistance, diabetes, and dyslipidemia. 3 In HIV-infected individuals, chronic inflammation and the use of ART may be associated with the development of NAFLD and progression to fibrosis. 4 Because of their immunomodulatory and anti-inflammatory properties beyond their lipidlowering and cardioprotective utility, statins have been suggested as candidates for the treatment and prevention of NAFLD in the general population. 5 HIV-infected individuals represent a unique population, and results from the general population on the effect of statins on NAFLD cannot be extrapolated directly to HIV-infected individuals. Antiretroviral treatment is known to alter lipid levels, and also interact with statin therapy. 6 This means that statins can have different lipid-lowering potencies and immunomodulatory effects in HIV-infected individuals compared with uninfected individuals. 7 Only a single recent small study assessed the effect of atorvastatin on liver fat in a group of HIV-infected individuals with NAFLD and showed an improvement in hepatic steatosis with statin therapy. 8 However, this study was limited by a very small sample size; 7 participants had NAFLD and only 3 of them were randomized to the atorvastatin arm.
Therefore, this study aimed to assess the effect of rosuvastatin on hepatic steatosis and fibrosis measured by the liver fat score (LFS) and the NAFLD fibrosis score (NAFLD-FS) in HIV-infected adults on stable ART and to investigate the predictors of hepatic steatosis progression over time. LFS and NAFLD-FS are noninvasive biomarkers used to predict liver steatosis and fibrosis, respectively. These scores are computed using clinical and laboratory parameters, allowing for the description of steatosis and fibrosis in patient populations not routinely undergoing radiographic imaging or liver biopsy. 9 
Methods
The earlier-described aims were assessed using data from the Stopping Atherosclerosis and Treating Unhealthy Bone With Rosuvastatin in HIV (SATURN-HIV) trial, which is a randomized, double-blind, placebocontrolled study designed to measure the effect of rosuvastatin on markers of cardiovascular risk and immune activation in HIV-infected adults. 10 The results presented herein represent a secondary analysis that assessed changes in LFS and NAFLD-FS from entry to week 48, and then week 96. SATURN-HIV was approved by the Institutional Review Board of University Hospitals Cleveland Medical Center, and all participants signed written informed consent before enrollment. Randomization was conducted with a 1:1 ratio to 10 mg rosuvastatin daily or matching placebo. Study drugs were provided by AstraZeneca (Wilmington, DE). SATURN-HIV is registered at clinicaltrials.gov (NCT01218802).
All authors had access to the study data, and reviewed and approved the final manuscript.
Study Population
Participants who met inclusion criteria were age 18 years and older, with HIV-1 infection, on stable ART for at least 3 months, HIV-1 RNA <1000 copies/mL, fasting low-density lipoprotein-cholesterol 130 mg/dL, and triglyceride levels 500 mg/dL. Additional entry criteria included evidence of either heightened T-cell activation and/or systemic inflammation
, and/or high-sensitivity C-reactive protein !2 mg/L). Participants were excluded if they had a history of coronary disease or diabetes, were pregnant or lactating, or had an active inflammatory condition. Further details have been published previously. 10 
Study Evaluations
Self-reported demographics and medical history were obtained along with a targeted physical examination. Subjects completed substance use and physical activity questionnaires, as well as a standardized dietary assessment. 11 No lifestyle or nutritional modification counseling was performed. Heavy alcohol consumption was defined as 4 or more drinks on any day in men and 3 or more drinks on any day in women.
What You Need to Know
Background Nonalcoholic fatty liver disease has emerged as a leading cause of morbidity and mortality in human immunodeficiency virus (HIV)-infected individuals, with no effective therapeutic interventions available in this population. Statins were shown to have a beneficial effect on nonalcoholic fatty liver disease in the general population, but their role in HIV remains unclear.
Findings
In a randomized controlled trial of rosuvastatin vs placebo, 147 HIV-infected individuals on stable antiretroviral therapy were followed up over 96 weeks. We found that hepatic steatosis increased over time, regardless of statin treatment, and was associated independently with markers of immune activation.
Implications for patient care
Despite their beneficial role in cardiovascular disease risk reduction, statins do not appear effective in mitigating hepatic steatosis in HIV-infected individuals on stable antiretroviral therapy.
At study entry, week 48, and week 96, fasting (>12 hours) blood draws were obtained for real-time measurements of liver and lipid profiles and glucose and insulin levels. In addition, blood was processed, and plasma, serum, and peripheral blood mononuclear cells were stored frozen at -80 C for batched measurements of inflammation and immune activation markers. HIV-1 RNA levels and CD4þ cell counts were drawn as part of clinical care. Insulin resistance was estimated using the homeostatic model assessment of insulin resistance. 12 All participants underwent dual-energy X-ray absorptiometry of the whole body as previously described. 13 
Outcome Measure
We computed LFS and NAFLD-FS at entry, week 48, and week 96. LFS, which has been validated in HIV-infected patients, 14 was computed using the following formula:
Metabolic syndrome was defined according to the criteria of the National Cholesterol Education Program. 15 An optimal cut-off value of -0.64 for LFS was determined previously 9 ; values greater than -0.64 predicted NAFLD with a sensitivity of 86% and a specificity of 71%. Increasing the cut-off value to 1.257 likewise increased the specificity of the test to 95%, however, sensitivity decreased to 52%. For this analysis, we selected LFS of 1.257 or greater for identification of participants with NAFLD because this cut-off level has been linked with higher cardiovascular and liver-related mortality, giving it clinical relevance. 16 NAFLD-FS was calculated according to the following formula: NAFLD-FS ¼ -1.675 þ 0.037 * age (years) þ 0.094 * body mass index (kg/m 2 ) þ 1.13 * impaired fasting glucose or diabetes (yes
. 17 A NAFLD-FS of 0.676 or greater has a positive predictive value for advanced fibrosis of 90%, whereas a NAFLD-FS of -1.455 or less had similar accuracy in excluding advanced fibrosis.
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Biomarkers of Inflammation and Immune Activation
T cells and monocytes were phenotyped by flow cytometry as previously described. 18 Levels of interleukin 6, TNF receptor superfamily member 1A and 1B, interferon g inducible protein-10 (IP-10), vascular and intercellular cell adhesion molecule 1, soluble CD14 (sCD14), and sCD163 were measured by enzyme-linked immunosorbent assay. 18 The D-dimer level was determined by immunoturbidimetric assay. Fibrinogen and high-sensitivity C-reactive protein levels were determined by particle-enhanced immunonephelometric assay. 19 
Statistical Analysis
This was an exploratory analysis to assist in developing hypotheses for future confirmatory studies. The main objective of this study was to compare changes in LFS and NAFLD-FS scores from baseline to 48 and baseline to 96 weeks between rosuvastatin and placebo groups. Secondary objectives were to evaluate within-group changes over time in these scores and to examine associations between baseline and changes in LFS with markers of systemic inflammation, immune activation, and insulin resistance.
Non-normal biomarkers were transformed using Box-Cox methods. Baseline variables were compared between groups, and absolute changes in LFS and NAFLD-FS across study weeks were calculated for each group. Between-and within-group changes were tested using paired t tests or Wilcoxon signed-rank tests, and unpaired t tests or Wilcoxon rank-sum tests as appropriate for the distribution of the variables, respectively. Linear regressions were used to assess relationships between baseline and changes in weeks 0 to 96 in LFS, randomization group, and clinically relevant factors. All variables with a P value less than .15 in univariable models were considered for inclusion in the multivariable models. Finally, logistic regression was used to model variables associated with the progression from no steatosis (LFS, <1.257) at baseline to liver steatosis (LFS, !1.257) at 96 weeks. Randomization group was the variable of interest in these models, which were adjusted for demographics, excessive alcohol, and change in homeostatic model assessment of insulin resistance over 96 weeks, each in separate models.
Results
Overall, 147 participants were enrolled and randomized in the SATURN-HIV study and were eligible for this analysis. A total of 28 participants (9 rosuvastatin, 19 placebo) were lost to follow-up evaluation or withdrew before 96 weeks, none because of adverse events. Therefore, this analysis included 128 participants at week 48 and 119 participants at week 96. The participant flow chart has been published previously. 10 
Baseline Characteristics
Baseline characteristics are presented in Table 1 and randomization groups were similar at baseline. Briefly, mean age and body mass index were 45 years and 28.1 kg/m 2 , respectively. Most were male (78%) and African American (68%). All participants were on ART by design (51% on a protease inhibitor and 5% on a thymidine analog), and most participants (78%) had an undetectable HIV-1 RNA level ( 48 copies/mL). The mean current and nadir CD4þ cell counts were 640 and 200 cells/mm 3 , respectively; 5% of patients had HIV transmission through intravenous drug use, and the remaining were through sexual contact. At baseline, 42% of participants had a LFS greater than -0.64 (47% vs 36%, for placebo vs rosuvastatin, respectively; P ¼ .19). However, more participants in the placebo group had a LFS of 1.257 or greater than the rosuvastatin group at baseline (28% vs 13%; P ¼ .02).
Changes in Liver Fat Score
Changes in LFS over 48 weeks were not statistically significant within or between groups (P ¼ .92 and P ¼ .21 for placebo and statin, respectively; P ¼ .54 between groups); however, by 96 weeks, there were significant increases in LFS in both the placebo (P ¼ .01) and statin arms (P < .01), but the changes were similar between groups (P ¼ .49).
After excluding participants with active co-infection with hepatitis B and/or C (a total of 19 participants were excluded, 8 in the rosuvastatin group and 11 in the placebo group), results were qualitatively unchanged (data not shown).
Interestingly, among HIV/hepatitis C and/or B co-infected participants who were followed up at 96 weeks (n ¼ 15; 6 in the rosuvastatin group and 9 in the placebo group), there was a significant decrease in LFS in the rosuvastatin arm (P ¼ .046), but not in the placebo arm (P ¼ .2); however, changes were not different between the groups (P ¼ .3). Individual components of LFS changes in HIV mono-infected and co-infected participants are presented in Supplementary Table 1 .
Changes in Nonalcoholic Fatty Liver Disease Fibrosis Score NAFLD-FS increased significantly within both groups from 0 to 48 weeks (P ¼ .013 and P < .001 for placebo and statin, respectively), and from 0 to 96 weeks (P ¼ .01 and P < .01, respectively). At both time points, however, these changes were similar between the groups (P ¼ .18 and P ¼ .52, respectively).
Factors Associated With Baseline and Changes in Weeks 0 to 96 in Liver Fat Score
Univariable and multivariable analyses exploring factors associated with baseline and changes in weeks 0 to 96 in LFS are presented in Table 2 . Although randomization group was not associated with a change in LFS in the univariable model, there was a trend toward significance in the multivariable model (P ¼ .06), suggesting randomization to rosuvastatin may have resulted in a greater increase in LFS over 96 weeks.
To further explore this finding, we evaluated whether randomization to rosuvastatin was associated with the progression from no steatosis at baseline to hepatic steatosis by 96 weeks. Of the 86 participants that did not have steatosis at baseline, or hepatitis B or C co-infection and had 96-week follow-up data, 13 (15%) progressed to steatosis by week 96; 10 in the rosuvastatin group, and 3 in the placebo group (P ¼ .13). Table 3 shows how the odds ratio for progression to steatosis in the rosuvastatin group compared with the placebo group changes when clinical factors potentially in the causal pathway are added to the model. Patients in the rosuvastatin group were nearly 3 times more likely to develop hepatic steatosis than patients in the placebo group, and it seems that change in insulin resistance over 96 weeks had the greatest impact on the odds ratio estimate, suggesting that this factor is likely an important link between rosuvastatin and the development of steatosis.
Discussion
In this study, established markers of liver steatosis and fibrosis increased significantly over 96 weeks in HIV-infected participants on stable ART, without any apparent beneficial effect of statin. In the absence of effective pharmacotherapy for hepatic steatosis and NAFLD-related fibrosis in HIV, statin therapy has been proposed as a potentially beneficial intervention 5 ; however, our preliminary findings failed to show a benefit in favor of statin. In addition, randomization to rosuvastatin may have resulted in a greater increase in hepatic steatosis over 96 weeks, a finding that highlights the need for further investigation.
Insulin resistance, oxidative stress, and inflammatory cascades are believed to play important roles in the pathogenesis and progression of NAFLD. 20 Consistent with the literature, both baseline LFS and the increase over 96 weeks were associated independently with different metabolic factors such as trunk fat and insulin resistance. 21 We previously reported in SATURN-HIV that 10 mg of daily rosuvastatin led to significant worsening in insulin resistance when compared with the placebo group. 13 Furthermore, our results show that an increase in insulin resistance over 96 weeks has the greatest impact on the development of steatosis, and, as such, the increase in insulin resistance in the rosuvastatin group may have contributed to the increase in hepatic steatosis in that group.
Hepatotoxicity with increased levels of AST and ALT have been reported as a frequent side effect of statin therapy. 22 In our study, changes in AST, ALT, and the AST/ALT ratio did not differ between the rosuvastatin and placebo groups.
Interestingly, we found that hepatic steatosis did not change over time among HIV/hepatitis B and/or C co-infected patients in the placebo group, but decreased in the rosuvastatin arm. These findings are consistent with recent findings in which hepatic steatosis was found to be higher and progress faster in HIV mono-infected patients compared with HIC/HCV co-infected patients. 23, 24 One recent study showed the beneficial effect of statins in reducing liver disease progression in HIV/HCV co-infected patients 25 ; however, the mechanism behind the differential effect of statin on hepatic steatosis in mono-infected vs co-infected patients seen in our findings is unknown, and possibly reflects a pathophysiological difference in hepatosteatosis between the 2 populations (metabolic vs virus-induced).
The direct impact of HIV was long thought to play a role in hepatic steatosis among HIV-infected individuals, although studies exploring this hypothesis have yielded inconsistent results. Interestingly, our analysis shows that baseline and change in LFS over time were associated independently with ART exposure and viral load. It is possible that antiretroviral medications or HIV itself may have led directly to the observed liver toxicity; persistent immune activation associated with chronic HIV infection or metabolic changes observed with ART (such as fat abnormalities, increased weight, or changes in lipoprotein levels) might have contributed to this toxicity.
In non-HIV-infected patients, circulating levels of the soluble monocyte activation marker sCD163 and IP-10 have been shown to predict the presence and severity of NAFLD. 26, 27 Consistent with these observations, our results show that hepatic steatosis was associated with higher baseline levels of sCD163 and IP-10, and the increase in LFS over time also was associated positively with baseline IP-10 levels. Increases in sCD163 and IP-10 also have been shown previously to predict non-acquired immune deficiency syndrome-related comorbidities in the HIV population, including cardiovascular disease and HIV-associated neurocognitive disorder. 28 Although the enhanced systemic inflammation in HIV may be contributing to liver steatosis, these relationships may be bidirectional, and so the increased inflammation from hepatic steatosis may potentiate already existing HIV-associated inflammation, further increasing the burden of other HIV-related comorbidities. Taken together, these findings might have important clinical relevance, suggesting that hepatic steatosis should be considered as part of the metabolic monitoring used to optimize cardiovascular risk profiles in this high-risk population. Further studies are warranted to determine the exact contribution of NAFLD to HIV-related comorbidities.
In the limited number of studies that evaluated the histologic changes in the NAFLD spectrum using liver biopsy in the HIV population, hepatic steatosis did not seem to progress to NASH and cirrhosis frequently. 29 In accordance with these results, we show that among participants with baseline hepatic steatosis, although NAFLD-FS increases were observed over time, they remained below the cut-off point predictive of fibrosis in HIV-uninfected populations. However, it is unclear if these increases would be clinically significant in the HIV population.
Despite the novelty of our findings, this study had some limitations that should be acknowledged. First, we used previously validated scores to assess for hepatic steatosis and fibrosis, recognizing that the gold standard for hepatic steatosis diagnosis remains liver biopsy. However, the invasive nature of this procedure makes it challenging to ethically justify its widespread use for assessment of liver steatosis without a specific clinical indication. More recently, imaging techniques also have been used to detect hepatic steatosis and fibrosis; however, these modalities are not widely available yet, are operator dependent, and are harder to integrate in the setting of HIV clinics. Because we recognized the limitation of the scores used, we used a higher cut-off point to detect hepatic steatosis that had more clinical relevance; this cut-off point had an increased specificity but decreased sensitivity, which potentially could have underestimated hepatic steatosis in our study. Finally, the majority of our patients were African American and men with low-density lipoprotein levels of 130 mg/dL or less, which may have made our results less generalizable to the entire HIV population.
In summary, in a 96-week randomized, doubleblinded, placebo-controlled trial of rosuvastatin in HIV-infected adults on ART, hepatic steatosis increased over time and possibly to a greater degree with rosuvastatin. Both HIV-related factors and markers of systemic inflammation and immune activation were associated with baseline hepatic steatosis and increases in LFS over time. These results call into question whether statin therapy would improve steatosis in HIV-infected adults on ART and call for further study.
